Featured Research

from universities, journals, and other organizations

Hormone deprivation therapy for prostate cancer may raise diabetes risk

Date:
June 6, 2011
Source:
The Endocrine Society
Summary:
Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy to block the production or action of male hormones that can fuel the growth of this cancer.

Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy (ADT) to block the production or action of male hormones that can fuel the growth of this cancer.

Related Articles


The results of this new study on the second-most common cancer in men were presented at The Endocrine Society's 93rd Annual Meeting in Boston.

"These patients may benefit from counseling, screening and closer monitoring for the development of these complications," said the study's lead author, Maria Luisa Cecilia Rivera-Arkoncel, MD, a fellow at the Philippine General Hospital in Manila.

This study adds to the scientific evidence that ADT may increase the chance of diabetes. Sometimes called medical or surgical castration, ADT is a common treatment when prostate cancer has spread outside the prostate. It can be permanent by surgically removing both testicles (bilateral orchiectomy), or, more often, temporary by using medications, such as gonadotropin-releasing hormone (GnRH) agonists, to prevent the testes from making testosterone.

In their study, Rivera-Arkoncel and her colleagues compared 38 men with prostate cancer who received ADT and 36 men with less advanced prostate cancer who did not receive hormonal therapy. Men in the ADT group either underwent bilateral orchiectomy at least six months earlier or received six or more months of treatment with injections of GnRH agonists. Both groups received treatment at the Philippine General Hospital from 2004 to 2010. Although the average age of the two groups was not the same at the beginning of the study, the groups were similar in terms of other diabetes risk factors, Rivera-Arkoncel said.

Based on a review of medical records, the researchers identified patients with Type 2 diabetes or the metabolic syndrome. This syndrome is a cluster of metabolic risk factors that increase the chance of developing diabetes, heart disease and stroke. The criteria used for diagnosis include a large waistline plus two of the following: low HDL ("good") cholesterol, high triglycerides (fats in the blood), high blood pressure and high blood sugar.

Men in the ADT group had a twofold increased probability of having diabetes after ADT, compared with the non-ADT group, Rivera-Arkoncel reported. According to the data, the prevalence of diabetes was 42 percent in the ADT group and 19 percent in the other group. In addition, the group receiving ADT had a higher prevalence of the metabolic syndrome than the non-ADT group did: 37 percent versus 28 percent, respectively.

"An increased risk of diabetes with ADT has not previously been demonstrated in the Filipino population, which already has a high prevalence of diabetes," she said.

She cautioned, however, that their cross sectional analytical study suggests, but cannot prove, that ADT is the cause of the increased prevalence of diabetes in men who received this hormonal therapy.

The Philippine Society for the Study of the Aging Male and the Philippine Urological Association funded this research.


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Hormone deprivation therapy for prostate cancer may raise diabetes risk." ScienceDaily. ScienceDaily, 6 June 2011. <www.sciencedaily.com/releases/2011/06/110604182012.htm>.
The Endocrine Society. (2011, June 6). Hormone deprivation therapy for prostate cancer may raise diabetes risk. ScienceDaily. Retrieved November 1, 2014 from www.sciencedaily.com/releases/2011/06/110604182012.htm
The Endocrine Society. "Hormone deprivation therapy for prostate cancer may raise diabetes risk." ScienceDaily. www.sciencedaily.com/releases/2011/06/110604182012.htm (accessed November 1, 2014).

Share This



More Health & Medicine News

Saturday, November 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins